2026 Predictions for Clinical Labs: AI, Audits, and Increased Enforcement
How clinical laboratories should prepare for the next wave of oversight in the new year
How clinical laboratories should prepare for the next wave of oversight in the new year
What clinical laboratory professionals need to know about healthcare provision for transgender and nonbinary patients
Curious about how laboratory-developed tests are regulated in other countries? We compare in-house test guidance across six regions
Though potential FDA LDTs regulation has drawn a lot of attention, other efforts could also have long-term effects on how labs do business.
Program outlined in a recently introduced bill would test AI’s effectiveness in detecting suspect payments for diagnostic tests and DME.
How clinical laboratory professionals can advocate for legislative and regulatory improvements
Joyce Gresko, partner at Alston & Bird, discusses the latest on PAMA and what will likely need to happen for SALSA to pass in 2024.
Comments on the FDA’s proposed rule to regulate LDTs as in vitro diagnostic devices reveal mixed reactions.
Genialis CEO and co-founder Rafael Rosengarten, PhD, discusses key 2023 AI developments and what they could mean for laboratories.
An overview of PAMA and key aspects lab compliance officers should be aware of to help ensure compliance.
On Oct. 28, the US Department of Health and Human Services served notice that it plans to repeal a controversial Trump rule.